Oculis Holding AG

OCS

Company Profile

  • Business description

    Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

  • Contact

    Bahnhofstrasse 20
    Zug6300
    CHE

    T: +41 417119325

    https://www.oculis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    49

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,828.7873.47-0.93%
DAX 4024,265.12191.69-0.78%
Dow JONES (US)44,416.92233.72-0.52%
FTSE 1008,940.9134.75-0.39%
HKSE24,139.57111.200.46%
NASDAQ20,625.934.74-0.02%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,262.0518.41-0.29%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers